The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), recently produced results […]
This week, Eli Lilly and Company and Incyte announced the publication of the New England Journal of Medicine’s peer-reviewed results […]
Back in late January, a British artificial intelligence (AI) venture known as BenevolentAI was employed to investigate thousands of potential drug […]
Eli Lilly recently announced more findings suggesting that it’s rheumatoid arthritis drug called baricitinib could improve the condition of patients […]
Four different clinical studies reveal that rheumatoid arthritis drug baricitinib may be effective in preventing cytokine storms—those severe immune system […]
Eli Lilly and Company announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled […]
Keck Medicine of USC physicians are launching a clinical trial to evaluate the efficacy and safety of baricitinib, an anti-inflammatory […]
The first possible treatment of COVID-19 identified by artificial intelligence moves into a randomized controlled trial. BenevolentAI’s technology has been […]
The University of Colorado, Denver will launch a clinical trial to evaluate a drug called baricitinib, approved for use in rheumatoid […]
